API
TEVA icon

Advisor Partners II’s Teva Pharmaceuticals TEVA Stock Holding History

Advisor Partners II’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$259K Buy
25,359
+9,757
+63% +$90.9K 0.01% 1035
2023
Q2 		$117K Buy
+15,602
New +$127K 0.01% 1047

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Advisor Partners II's TEVA Position: Q3 2023 in Review

Advisor Partners II increased its Teva Pharmaceuticals (TEVA) stake by 63% in Q3 2023, buying an estimated $90.9K and bringing the position to 25,359 shares worth $259K. The position accounts for 0.01% of the portfolio, ranked #1035.

Advisor Partners II first reported a position in TEVA in Q2 2023 and has held it in 2 quarters since. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Advisor Partners II held 25,359 shares of Teva Pharmaceuticals worth $259K as of Q3 2023.
  • Advisor Partners II bought 9,757 Teva Pharmaceuticals shares in Q3 2023, an estimated $90.9K.
  • Teva Pharmaceuticals made up 0.01% of Advisor Partners II's portfolio in Q3 2023, its #1035 holding.
  • Advisor Partners II first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.